Marion Subklewe, MD, LMU Hospital Munich, Munich, Germany, shares some insights into how the efficacy of bispecific antibodies can be improved in the treatment of acute myeloid leukemia (AML) from a pre-clinical perspective. Dr Subklewe highlights some findings which show that the addition of another bispecific antibody which translates a positive co-stimulatory molecule can enhance T-cell function, greatly improving the efficacy of this treatment regimen in AML. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.